Total Cancer Incidence and Overall Mortality Are Not Increased Among Patients With Barrett's Esophagus

被引:37
|
作者
Schouten, Leo J. [1 ]
Steevens, Jessie [1 ]
Huysentruyt, Clement J. R. [2 ]
Coffeng, Ceciel E. [1 ]
Keulemans, Yolande C. A. [3 ]
van Leeuwen, Floor E. [4 ]
Driessen, Ann L. C. [2 ]
van den Brandt, Piet A. [1 ]
机构
[1] Maastricht Univ, Dept Epidemiol, GROW Sch Oncol & Dev Biol, Med Ctr, NL-6200 MD Maastricht, Netherlands
[2] Maastricht Univ, Dept Pathol, GROW Sch Oncol & Dev Biol, Med Ctr, NL-6200 MD Maastricht, Netherlands
[3] Maastricht Univ, Dept Gastroenterol, Med Ctr, NL-6200 MD Maastricht, Netherlands
[4] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands
关键词
Esophagus; Stomach; Tumor; Prognosis; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX; FOLLOW-UP; RISK; ADENOCARCINOMA; NETHERLANDS; REGISTRY; COHORT; METAANALYSIS; GUIDELINES;
D O I
10.1016/j.cgh.2011.04.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Barrett's esophagus (BE) increases risk for esophageal adenocarcinoma, but it is not clear how it affects risk for other cancers or overall mortality. We analyzed data from a population-based cohort of subjects with BE. METHODS: The Netherlands Cohort Study was initiated in 1986 and included 120,852 participants (55-69 years old at baseline). Until December 2002, 626 incident cases of BE (excluding nonintestinal metaplasia) were identified by record linkage with the nationwide Pathology Registry. This cohort was followed for a median period of 5.7 years; data on cancer and mortality were obtained from record linkage to the Netherlands Cancer Registry and Statistics Netherlands. The expected number of cases was calculated using national cancer incidence and mortality data. RESULTS: In the BE cohort, 13 individuals developed esophageal cancer and 5 developed gastric cancer. The ratio of observed: expected (O:E) incidence of esophageal and gastric cancer was 10.0 (95% confidence interval [CI], 5.3-17.1) and 1.8 (95% CI, 0.6-4.2), respectively. Total cancer incidence (excluding esophageal and gastric cancer) increased in the BE cohort, although not by a statistically significant amount (O: E, 1.3; 95% CI, 1.0-1.6). Of cancer subtypes, incidences of small intestinal and pancreatic cancer increased in subjects with BE, but not by a statistically significant amount, after exclusion of data from the first 6 months of follow-up. During the follow-up period, 225 individuals with BE died. Mortality from all causes (excluding esophageal and gastric cancer) was not increased among subjects with BE (O: E, 1.0; 95% CI, 0.9-1.2), nor was mortality from specific causes of death. CONCLUSIONS: The incidence of esophageal cancer was increased in a population-based cohort of subjects with BE. However, when esophageal and gastric cancers were excluded, total cancer incidence and overall mortality were not increased among subjects with BE.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 50 条
  • [1] Risk of mortality and cancer incidence in Barrett's esophagus
    Cook, Michael B.
    Wild, Chris P.
    Everett, Simon
    Hardie, Laura J.
    Forman, David
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A53 - A53
  • [2] Risk of mortality and cancer incidence in Barrett's esophagus
    Cook, Michael B.
    Wild, Christopher P.
    Everett, Simon M.
    Hardie, Lauraj.
    Bani-Hani, Kamal E.
    Martin, Iain G.
    Forman, David
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (10) : 2090 - 2096
  • [3] Incidence of Adenocarcinoma among Patients with Barrett's Esophagus
    Hvid-Jensen, Frederik
    Pedersen, Lars
    Drewes, Asbjorn Mohr
    Sorensen, Henrik Toft
    Funch-Jensen, Peter
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15): : 1375 - 1383
  • [4] The impact of Barrett's esophagus on overall survival of colon cancer patients
    Mozayen, M.
    Omaira, M.
    Kanaan, M.
    Katato, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Mortality in Patients With Barrett's Esophagus (BE)
    Caygill, Christine P.
    Royston, Christine
    Charlett, Andre
    Wall, Christine
    Gatenby, Piers A.
    Ramus, James R.
    Watson, Anthony
    Winslet, Marc C.
    Bardhan, Karna D.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S16 - S16
  • [6] Selected commentary to "Incidence of adenocarcinoma among patients with Barrett's esophagus"
    Schoppmann, S. F.
    Azari, R.
    Riegler, F. M.
    [J]. EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2012, 44 (04): : 291 - 295
  • [7] Selected commentary to "Incidence of adenocarcinoma among patients with Barrett's esophagus"
    S. F. Schoppmann
    R. Azari
    F. M. Riegler
    [J]. European Surgery, 2012, 44 : 291 - 295
  • [8] Cancer Incidence and Mortality Risks in a Large United States Barrett's Esophagus Cohort
    Cook, Michael B.
    Behan, Sally
    Zhao, Wei K.
    Udaltsova, Natalia
    Taylor, Philip R.
    Schneider, Jennifer L.
    Corley, Douglas
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S852 - S853
  • [9] Low incidence of cancer in patients with high grade dysplasia in Barrett's esophagus
    Selvasekar, CR
    Thorpe, S
    Novelli, MR
    Bown, SG
    Lovat, LB
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A309 - A309
  • [10] The Incidence of Gastroesophageal Reflux Disease and Barrett's Esophagus is Increased in Patients With Cervical Inlet Patch
    Rosztoczy, Andras I.
    Dulic, Sonja
    Nemeth, Istvan
    Izbeki, Ferenc
    Roka, Richard
    Gecse, Krisztina
    Gyokeres, Tibor
    Kiss, Ildiko
    Tiszlavicz, Laszlo
    Wittmann, Tibor
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S560 - S560